S2L.DU Stock Analysis
S2
Uncovered
Bausch + Lomb Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 12,900 full-time employees. The company went IPO on 2022-05-06. The firm operates through three segments: Vision Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter (OTC) eye drops and eye vitamins. The Ophthalmic Pharmaceuticals segment consists of a line of generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes intraocular lenses and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery.